Skip to main content
SpringerLink
Log in

Our reasons for converting to valproic acid treatment in female patients with genetic generalized epilepsy: a retrospective, single-centre study

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Introduction and Aim

Valproic acid (Na valproate) is a broad-spectrum anti-seizure medication used in children and adolescents. It is thought to have fewer adverse effects; however, recent studies have restricted its use in women of reproductive age due to the teratogenic impacts on cognition. Although alternative drugs have been used to treat patients in clinical follow-up, some patients have to return to using valproic acid. Our study aimed to determine the rate of return to valproic acid treatment in female patients with follow-up in our centre and the reasons for the return.

Materials and Methods

Female patients with genetic generalized epilepsy who were followed up in our centre were included in the study. Patient data were retrospectively obtained from file records. The patients were grouped by seizure subgroups, antiepileptic treatment used, electroencephalography characteristics, and seizure treatment response.

Results

Sixty-three (31.7%) of the 199 patients had to return to VPA treatment. When the reasons for the discontinuation of other drugs were examined, non-response to treatment was found in 80.0% of patients, adverse medication effects in 18.3%, and 1.7% continued voluntarily. Patients who are JAE subtypes were more likely to return to VPA treatment than GTCS alone subtypes. A total of 7.4% of patients converted to VPA therapy had continued myoclonic seizures compared with 20.4% of patients treated with alternative drugs.

Conclusion

VPA treatment is not used as the first choice in females of reproductive age; however, some patients will only achieve seizure control with valproate, especially those with myoclonic seizures and JAE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Davis R, Peters DH, McTavish D (1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:332–372

    Article  CAS  Google Scholar 

  2. Eriksson K, Viinikainen K, Mönkkönen A, Äikiä M, Nieminen P, Heinonen S, Kälviäinen R (2005) Children exposed to valproate in utero: population-based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65(3):189–200

    Article  CAS  Google Scholar 

  3. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP study group (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10(7):609–617

    Article  CAS  Google Scholar 

  4. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597–1605

    Article  CAS  Google Scholar 

  5. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12(3):244–252. https://doi.org/10.1016/S1474-4422(12)70323-X

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, Garcia-Finana M, Gummery A, Kneen R, Loring DW, Mawer G, Meador KJ, Shallcross R, Clayton-Smith J, On behalf of the Liverpool and Manchester Neurodevelopment Group (2015) IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84(4):382–390

    Article  CAS  Google Scholar 

  7. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76(4):383–389

    Article  CAS  Google Scholar 

  8. Shallcross R, Bromley RL, Cheyne CP, Garcia-Finana M, Irwin B, Morrow J et al (2014) In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 82(3):213–221

    Article  CAS  Google Scholar 

  9. Christensen J, Gronborg TK, Sorensen MJ et al (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 309:1696–1703

    Article  CAS  Google Scholar 

  10. Bromley RL, Calderbank R, Cheyne CP, Rooney C, Trayner P, Clayton-Smith J, García-Fiñana M, Irwin B, Morrow JI, Shallcross R, Baker GA, UK Epilepsy and Pregnancy Register (2016) Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 87:1943–1953

    Article  CAS  Google Scholar 

  11. Rihtman T, Parush S, Ornoy A (2012) Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol 34(3):308–311

    Article  CAS  Google Scholar 

  12. IE Scheffer et al ILAE Classification of the Epilepsies Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512-521).

  13. Epilepsies: diagnosis and management Clinical guideline [CG137] Published date: 11 January 2012 Last updated: 11 February 2020.

  14. Seneviratne U, Hepworth G, Cook M, D'Souza W (2016) Atypical EEG abnormalities in genetic generalized epilepsies. Clin Neurophysiol 127(1):214–220

    Article  Google Scholar 

  15. Bosak M, Słowik A, Turaj W (2019) Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. Epilepsy Behav 98:1–5

    Article  Google Scholar 

  16. Posner EB, Mohamed K, Marson AG (2005) Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 4:CD003032

    Google Scholar 

  17. Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, Faught RE (2003) Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 60(8):1100–1105

    Article  Google Scholar 

  18. de Almeida Campos MS et al (2018) Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm 40(3):589–598

    Article  Google Scholar 

  19. Striano P, Sofia V, Capovilla G, Rubboli G, di Bonaventura C, Coppola A, Vitale G, Fontanillas L, Giallonardo AT, Biondi R, Romeo A, Viri M, Zara F, Striano S (2008) A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia. 49(3):425–430

    Article  CAS  Google Scholar 

  20. Kim HL, Aldridge J, Rho JM (2005) Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 20(3):212–219

    Article  Google Scholar 

  21. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, On behalf of the Levetiracetam N01057 Study Group (2007) On behalf of the Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 69(18):1751–1760

    Article  CAS  Google Scholar 

  22. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J, For the N166 Levetiracetam Study Group (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 70(8):607–616

    Article  CAS  Google Scholar 

  23. Nicolson A, Appleton RE, Chadwick DW, Smith DF (2004) The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry 75(1):75–79

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A (2004) Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 6(4):267–270

    PubMed  Google Scholar 

  25. Morris GL, Hammer AE, Kustra RP, Messenheimer JA (2004) Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 5(4):509–512

    Article  Google Scholar 

  26. Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R, SP0982 co-investigators (2020) Efficacy and safety of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: a double-blind, randomized, placebo-controlled trial. J Neurol Neurosurg Psychiatry 91(10):1067–1075

    Article  Google Scholar 

  27. Cerulli Irelli E, Morano A, Cocchi E et al (2019) Doing without valproate in women of childbearing potential with Idiopathic generalized epilepsy: Implications on seizure outcome. Epilepsia. 00:1–8

    Google Scholar 

  28. Gesche J et al (2020) Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology:95/18

  29. Cerulli Irelli E, Cocchi E, Morano A, Casciato S, Fanella M, Albini M, Fisco G, Barone FA, Orlando B, Mascia A, Manfredi M, Fattouch J, Giallonardo AT, di Gennaro G, di Bonaventura C (2020) Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy. J Neurol Sci 415:116940

    Article  Google Scholar 

  30. Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, Kälviäinen R, Trinka E (2015) Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 56(7):1006–1019. https://doi.org/10.1111/epi.13021

    Article  CAS  PubMed  Google Scholar 

  31. Angus-Leppan H, Moghim MM, Cock H, Kinton L, Wells MS, Shankar R (2020) Valproate risk form—Surveying 215 clinicians involving 4775 encounters. Acta Neurol Scand 141:483–490

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Clinical Neurophysiology, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey

    Dilara Mermi Dibek, İbrahim Öztura & Barış Baklan

Authors
  1. Dilara Mermi Dibek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. İbrahim Öztura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barış Baklan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors managed the patients, performed the analysis, wrote and reviewed the manuscript, and approved the final version of the manuscript.

Corresponding author

Correspondence to Dilara Mermi Dibek.

Ethics declarations

Ethical approval

Ethics committee approval of Dokuz Eylul University (No.: 2020 / 17-25) was obtained.

Informed consent

None.

Conflict of interest

The authors declare that there are no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mermi Dibek, D., Öztura, İ. & Baklan, B. Our reasons for converting to valproic acid treatment in female patients with genetic generalized epilepsy: a retrospective, single-centre study. Neurol Sci 43, 517–523 (2022). https://doi.org/10.1007/s10072-021-05261-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05261-8

Keywords

Search

Navigation